Drug
Ombitasvir clinical trials
Also written ABT-267.
Counted the way a researcher would: Ombitasvir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2015 (14)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 4 |
| 2015 | 14 |
| 2016 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 7
AbbVie (20) · AbbVie (prior sponsor, Abbott) (9) · Nova Scotia Health Authority (1) · Kirby Institute (1) · Humanity and Health Research Centre (1) · Assiut University (1) · American Research Corporation (1) · Abbott (1)
Often tested with
Tested in the same studies.
Paritaprevir (33) · Ritonavir (33) · Dasabuvir (27) · Ribavirin (24) · Sofosbuvir (3) · Ombitasvir/Paritaprevir/Ritonavir (3) · Glecaprevir and pibrentasvir (1) · Ledipasvir, sofosbuvir drug combination (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses ombitasvir is read from its arms, and is right about nine times in ten.
Testing it · 37
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV TreatmentActive, not recruitingPhase 4Nova Scotia Health AuthorityNCT02460133Written as Ombitasvir
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02219490Written as ABT-450/r/ABT-267
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PCompletedPhase 3Kirby InstituteNCT02634008Written as Paritaprevir/ritonavir/ombitasvir
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02167945Written as ABT-450/r/ABT-267
- Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral TherapyTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02194998Written as Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedPhase 2/3Humanity and Health Research CentreNCT02555943Written as Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
- A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced AdultsCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01715415Written as ABT-450/r/ABT-267, ABT-333
- Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02023112Written as ABT-450/r/ABT-267
- A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated CirrhosisCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01704755Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate Chronic Hepatitis C InfectionCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01716585Written as ABT-450/r/ABT-267, ABT-333
- Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney DiseaseCompletedPhase 4Assiut UniversityNCT03499639Written as Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
- Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus InfectionCompletedPhase 3AbbVieNCT02609659Written as ombitasvir/paritaprevir/ritonavir and dasabuvir
- A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND StudyCompletedPhase 4American Research CorporationNCT03710252Written as paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
- ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated CirrhosisCompletedPhase 3AbbVieNCT02517528Written as ABT-450/r/ABT-267
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected SubjectsCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01563536Written as ABT-267
- Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected SubjectsCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01314261Written as ABT-267
- Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02023099Written as ABT-450/r/ABT-267
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedPhase 3AbbVieNCT01854697Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced AdultsCompletedPhase 3AbbVieNCT01854528Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus InfectionCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01672983Written as ABT-450/ritonavir, ABT-267
See all 37 studies that test ombitasvir →
Given in every arm · 8 — ombitasvir is usual care beside what is tested
- A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric SubjectsCompletedPhase 2/3AbbVieNCT02486406Written as Ombitasvir mini tablet
- A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus InfectionCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01685203Written as ABT-267
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b InfectionCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01767116Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis CCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01674725Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)CompletedPhase 2AbbVieNCT01995071Written as ABT-450/r/ABT-267, ABT-333
- A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionCompletedPhase 2/3AbbVieNCT01939197Written as ABT-450/r/ABT-267
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a InfectionCompletedPhase 3AbbVieNCT01833533Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination StudyCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01609933Written as ABT-267
Codes
What other systems call ombitasvir · ClinicalTrials.gg INT006422
- MeSH (NLM) C586094ombitasvirOne source NLM
- UNII (FDA) 2302768XJ8OMBITASVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1597371Confirmed FDA, Wikidata
- Wikidata Q19598175ombitasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C123878OmbitasvirOne source FDA
- DrugBank DB09296One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C586094 | ombitasvir | One source NLM |
| UNII (FDA) | 2302768XJ8 | OMBITASVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1597371 | — | Confirmed FDA, Wikidata |
| Wikidata | Q19598175 | ombitasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C123878 | Ombitasvir | One source FDA |
| DrugBank | DB09296 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.